How a drug goes from lab to pharmacy

The stake: many toxic or useless candidates die here, which is good. Killing a bad drug early is cheap. Killing it in Phase 3 is catastrophic.

Stage 3: Clinical Trials (the expensive part)

Human testing runs in three phases. Each is bigger, costlier, and more revealing than the last. The FDA's own overview is a clear, free primer.

Phase 1: Is it safe?

A small group (typically 20 to 100 healthy volunteers) receives the drug. The question is tolerability and dosing, not whether it cures anything. What dose is safe? How does the body process it?

Phase 2: Does it work at all?

A few hundred patients who actually have the disease. Here the company looks for a signal of effectiveness and watches side effects closely. Many drugs fail here because the promising lab result simply does not hold up in real patients.

Phase 3: Does it work, reliably, at scale?

Hundreds to thousands of patients, often across many countries and hospitals. These trials are usually randomized and controlled: patients are randomly assigned to the new drug or to a comparison (a placebo or the current standard treatment), so the results are trustworthy.

Phase 3 is where budgets explode. A single large Phase 3 program can cost hundreds of millions of dollars.

The stake: this is the industry's cliff. A drug can pass Phase 1 and Phase 2, then fail Phase 3, wiping out a decade of investment. Historically, only around 10% of drugs that enter Phase 1 ever get approved. That attrition is why one winner has to pay for many losers.

Stage 4: Regulatory Approval

If the trials succeed, the company submits the full evidence package to regulators:

• In the US: an NDA (New Drug Application) for small molecules or a BLA (Biologics License Application) for biologics, reviewed by the FDA.
• In Europe: an application to the EMA (European Medicines Agency), which coordinates review across EU member states.

Reviewers scrutinize the data, the manufacturing plans, and the proposed label. They can approve, reject, or ask for more studies. The FDA also convenes independent advisory committees for tough cases; these panels vote publicly, though the FDA makes the final call.

Approval is not global. A drug cleared by the FDA still needs EMA approval to sell in Europe, and separate approvals elsewhere (Japan's PMDA, China's NMPA, and so on). Each regulator can reachreachThe number of unique people exposed to your message in a given period. Unlike impressions, reach counts each person once, no matter how often they see it.Voir la définition complète → a different conclusion.

The stake: timing. Every month of delay is a month of patent life burning while the drug earns nothing. Regulators offer accelerated pathways (the FDA's Breakthrough Therapy and Fast Track designations, for example) for drugs targeting serious unmet needs.

Stage 5: Manufacturing

Approval means you are allowed to sell the drug. Now you have to actually make it, at scale, at consistent quality, every single batch.

This is harder than it sounds, especially for biologics grown in living cells, where tiny changes in temperature or process can alter the product. Facilities must follow GMP (Good Manufacturing Practice), enforceable quality rules that regulators inspect. A failed inspection can shut down supply.

Two realities shape this stage:

• Supply chains are global and concentrated. A large share of active ingredients is produced in a handful of countries, notably India and China. This concentration became a policy concern after COVID-era shortages, and reshoring is now a live debate in 2026.
• Cold chain matters. Many biologics and vaccines must stay refrigerated or frozen from factory to patient. The COVID-19 mRNA vaccines, some requiring ultra-cold storage, made this famous.

The stake: you can have a brilliant drug and still fail commercially if you cannot supply it reliably.

Stage 6: Commercialization

Now the drug reaches doctors and patients. This involves:

• Pricing and reimbursement. In most countries, a government or insurer, not the patient, decides what to pay. In Europe, agencies negotiate price against proven benefit. In the US, negotiations run through insurers and PBMs (Pharmacy Benefit Managers), intermediaries who manage drug coverage.
• Market access. Getting onto insurers' approved lists (formularies) is often as important as the science.
• Sales and medical education. Informing physicians about when and how to use the drug.

Meanwhile the clock is ticking on the patent, typically 20 years from filing, but much of that is consumed during development. A drug may reachreachThe number of unique people exposed to your message in a given period. Unlike impressions, reach counts each person once, no matter how often they see it.Voir la définition complète → the market with only 8 to 12 years of exclusivity left.

When patents expire, cheap generics (for small molecules) or biosimilars (for biologics) enter, and revenue can drop sharply. This moment is called the patent cliff, and it drives much of the industry's urgency to keep discovering the next drug.

The stake: the commercial window is short. Companies must recoup the entire cost of development, including all the failures, before exclusivity ends.

Why the Industry Behaves the Way It Does

Now the pattern makes sense:

• High prices on new drugs reflect the need to recover roughly a billion dollars of sunk cost, including failures, within a limited patent window.
• Merger activity often reflects large firms buying smaller biotechs that own a promising late-stage molecule, effectively purchasing a shot at the next blockbuster.
• Caution and paperwork reflect a regulated environment where one safety failure can end a product and damage a company.

None of this is an endorsement or a criticism. It is the logic that a 10 to 15 year, high-attrition, heavily regulated pipelinepipelineAll active sales opportunities across the stages of the sales process, together with their combined potential value and probability of closing.Voir la définition complète → produces.

Key Takeaways

• The pharma value chain runs discovery, preclinical, three clinical phases, regulatory approval, manufacturing, and commercialization, typically over 10 to 15 years.
• Risk is concentrated in clinical trials: only about 10% of drugs entering Phase 1 reachreachThe number of unique people exposed to your message in a given period. Unlike impressions, reach counts each person once, no matter how often they see it.Voir la définition complète → approval, and Phase 3 failures are the industry's biggest financial cliff.
• Approval is regulator-specific: FDA (US) and EMA (Europe) review separately, and clearance in one market does not guarantee another.
• Manufacturing and supply (GMP, cold chain, concentrated global sourcing) can make or break an approved drug.
• The patent cliff and short commercial window explain pharma's pricing, its constant hunt for new molecules, and its appetite for acquiring biotech pipelines.